memantine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 111 Diseases   73 Trials   73 Trials   1509 News 


«12...89101112131415161718...3637»
  • ||||||||||  diphenhydramine / Generic mfg., memantine / Generic mfg.
    Preclinical, Journal:  Increased brain penetration of diphenhydramine and memantine in rats with adjuvant-induced arthritis. (Pubmed Central) -  Mar 19, 2022   
    OCT mRNA levels were increased and proton-coupled organic cation (H/OC) antiporter mRNA levels were decreased in AA rats compared with control rats. Taken together, our findings suggest that inflammation decreases the brain penetration of H/OC antiporter substrates such as DPHM and MMT.
  • ||||||||||  ketamine / Generic mfg., memantine / Generic mfg.
    Review, Journal:  Glutamate Nmda Receptor Antagonists With Relevance To Schizophrenia: A Review Of Zebrafish Behavioral Studies. (Pubmed Central) -  Mar 18, 2022   
    Frequently reported findings are the social interaction and memory deficits induced by MK-801 and circling behavior induced by ketamine...We conclude that zebrafish is a suitable model organism to study drug-induced behavioral phenotypes relevant to schizophrenia. However, more studies are necessary to further characterize the major differences in behavior as compared to mammals.
  • ||||||||||  memantine / Generic mfg.
    Journal:  Memantine Alleviates Acute Lung Injury via Inhibiting Macrophage Pyroptosis. (Pubmed Central) -  Mar 18, 2022   
    In this study, we demonstrate that memantine, a N-methyl-D-aspartic acid receptor (NMDAR) antagonist, through suppressing Ca2+ influx and subsequent ASC oligomerization inhibits macrophage Nlrp3 inflammasome activation and pyroptosis, therefore, alleviates ALI in septic mice. This finding explores a novel application of memantine, an FDA already approved medication, in the treatment of ALI, which is currently lacking effective therapy.
  • ||||||||||  memantine / Generic mfg.
    Trial completion, Trial completion date:  Memantine for Epileptic Encephalopathy (clinicaltrials.gov) -  Mar 11, 2022   
    P4,  N=30, Completed, 
    Nevertheless, the current results don`t support the efficacy of memantine as an adjunctive agent to sertraline for symptoms in patients with OCD. Recruiting --> Completed | Trial completion date: May 2022 --> Feb 2022
  • ||||||||||  memantine / Generic mfg.
    Clinical, Journal:  Alzheimer's Disease THErapy With NEuroaid (ATHENE): A Randomized Double-Blind Delayed-Start Trial. (Pubmed Central) -  Mar 8, 2022   
    P2
    This study of 125 persons with dementia found no evidence of a significant increase in adverse events between MLC901 and placebo, thus providing support for further studies on both efficacy and safety. Analyses suggest the potential of MLC901 in slowing down AD progression, but this requires further confirmation in larger and longer studies using biomarkers for AD.
  • ||||||||||  galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
    Rational Prescribing of Antidementia Agents to Medicare Beneficiaries (Virtual) -  Mar 8, 2022 - Abstract #ISPOR2022ISPOR_1681;    
    Conclusions : The findings suggest that prescribers are limiting the use of antidementia drugs to donepezil and memantine. Future studies may examine if prescribing these drugs is associated with fewer adverse drug events and favorable health outcomes than other antidementia agents.
  • ||||||||||  memantine / Generic mfg.
    Review, Journal:  Blood-Brain Barrier Transporters: Opportunities for Therapeutic Development in Ischemic Stroke. (Pubmed Central) -  Mar 5, 2022   
    Additionally, we provide state-of-the-art perspectives on how transporter pharmacology can be integrated into preclinical stroke research. Specifically, we discuss the utility of in vivo stroke models to transporter studies and considerations (i.e., species selection, co-morbid conditions) that will optimize the translational success of stroke pharmacotherapeutic experiments.
  • ||||||||||  methylphenidate tablet / Generic mfg., memantine / Generic mfg.
    Journal:  Methylphenidate and Other Pharmacologic Treatments for Apathy in Alzheimer's Disease. (Pubmed Central) -  Mar 3, 2022   
    A reasonable conclusion is that whereas MPH may attenuate the severity of apathy in patients with AD across as long as 6 months, the absence of improvements in measures of dependence, activities of daily living, and quality of life suggest that this effect of MPH on apathy may not be clinically significant. An unanswered question is whether the benefits of MPH may be clinically significant in real world practice settings in which the delivery of behavioral interventions is not feasible.
  • ||||||||||  memantine / Generic mfg.
    Journal:  Racial/ethnic disparities in initiation and persistent use of anti-dementia medications. (Pubmed Central) -  Feb 27, 2022   
    MDD seems to be initiated when use of psychotropics is initiated and the number of drugs increases. Substantial racial/ethnic treatment disparities remain in controlled settings of longitudinal research in which participants have access to dementia experts, suggesting wider disparities in the larger community.
  • ||||||||||  memantine / Generic mfg.
    Preclinical, Journal:  Cerebroprotective effect of Aloe Emodin: In silico and in vivo studies. (Pubmed Central) -  Feb 25, 2022   
    It can be concluded that AE showed cerebroprotective effect on RO/RCA with promising inhibition of cerebrotoxic proteins (apoptotic and neuroinflammatory) as evident from molecular docking studies. The cerebroprotective potential of AE could be due to its anti-inflammatory, antioxidant, and antiapoptotic principles.
  • ||||||||||  memantine / Generic mfg.
    Clinical, Journal:  Effect of Memantine on QT/QTc Interval in a Healthy Korean Population. (Pubmed Central) -  Feb 23, 2022   
    Regression analysis was performed based on the results; there was no statistical association between memantine blood level and QT prolongation. In conclusion, the results of the present study demonstrated no clinically significant changes in the QT interval with therapeutic blood levels of memantine.
  • ||||||||||  memantine / Generic mfg.
    Retrospective data, Journal:  A retrospective analysis of memantine use in a pediatric neurology clinic. (Pubmed Central) -  Feb 22, 2022   
    MEM may exert its anti-infective effects by promoting neutrophilic bactericidal activity via increasing the expression level of p67phox and further stimulating ROS generation. Memantine is generally well-tolerated in children, and may have potential benefit for a broad range of pediatric neurodevelopmental disorders.
  • ||||||||||  memantine / Generic mfg.
    Journal:  Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. (Pubmed Central) -  Feb 22, 2022   
    Memantine and hippocampal avoidance should be offered to patients who receive whole brain radiation therapy and have no hippocampal lesions and 4 months or more expected survival. Patients with asymptomatic brain metastases with either Karnofsky Performance Status ≤ 50 or Karnofsky Performance Status < 70 with no systemic therapy options do not derive benefit from radiation therapy.Additional information is available at www.asco.org/neurooncology-guidelines.
  • ||||||||||  memantine / Generic mfg.
    Clinical, Review, Journal:  Mechanistic insights into the efficacy of memantine in treating certain drug addictions. (Pubmed Central) -  Feb 19, 2022   
    In conclusion, memantine remains an intriguing compound in our pharmacopeia with controversial results in treating certain aspects of drug addiction. Further studies are needed to understand the clinical and biological correlates of its efficacy.
  • ||||||||||  memantine / Generic mfg.
    Trial suspension, Trial primary completion date:  ClearMEMory: Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus (clinicaltrials.gov) -  Feb 18, 2022   
    P2,  N=80, Suspended, 
    Further studies are needed to understand the clinical and biological correlates of its efficacy. Recruiting --> Suspended | Trial primary completion date: Oct 2022 --> Jan 2022
  • ||||||||||  memantine / Generic mfg.
    Journal, IO biomarker:  Modulatory Effects of Alpha-Mangostin Mediated by SIRT1/3-FOXO3a Pathway in Oxidative Stress-Induced Neuronal Cells. (Pubmed Central) -  Feb 15, 2022   
    A molecular docking study predicted that alpha-mangostin is directly bound to the active site of SIRT1. Findings from this study suggest that alpha-mangostin potentially serves as a promising therapeutic compound against oxidative stress by activation of the SIRT1/3-FOXO3a pathway comparable to the effect of memantine, an anti-AD drug used for the treatment of moderate to severe dementia.
  • ||||||||||  LMTX (hydromethylthionine) / TauRx
    Journal:  Hydromethylthionine enhancement of central cholinergic signalling is blocked by rivastigmine and memantine. (Pubmed Central) -  Feb 12, 2022   
    Our findings establish that the drug interaction that was first observed clinically has a neuropharmacological basis and is not restricted to animals with tau aggregation pathology. Given the importance of the cholinergic system for memory function, the potential for commonly used AD drugs to interfere with the treatment effects of disease-modifying drugs needs to be taken into account in the design of clinical trials.
  • ||||||||||  galantamine hydrobromide / Generic mfg., memantine / Generic mfg.
    Review, Journal:  Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders. (Pubmed Central) -  Feb 11, 2022   
    In line with this hypothesis, KYNA may be considered as the "conductor of the orchestra" for the major pathophysiological mechanisms underlying CNS disorders. Therefore, there is great opportunity to further explore and compare the biological effects of these therapeutic modalities in animal models with a special focus on their effects on KP metabolites in the CNS and with the ultimate goal of progressing to clinical trials for many neuropsychiatric diseases.
  • ||||||||||  memantine / Generic mfg.
    Review, Journal:  Pharmacologic neuroprotection in ischemic brain injury after cardiac arrest. (Pubmed Central) -  Feb 9, 2022   
    In this review article, we discuss a number of different pharmacologic agents that may have a potential role in targeting these injurious pathways following cardiac arrest. Pharmacologic therapies most relevant for discussion currently include memantine, perampanel, magnesium, propofol, thiamine, methylene blue, vitamin C, vitamin E, coenzyme Q , minocycline, steroids, and aspirin.
  • ||||||||||  memantine / Generic mfg.
    Review, Journal:  New Pharmacological Targets for the Treatment of Schizophrenia: A Literature Review. (Pubmed Central) -  Feb 9, 2022   
    Pharmacologic therapies most relevant for discussion currently include memantine, perampanel, magnesium, propofol, thiamine, methylene blue, vitamin C, vitamin E, coenzyme Q , minocycline, steroids, and aspirin. This narrative report suggests a promising role of new agents in the treatment of Schizophrenia; however, more research is needed to approve their clinical employment.
  • ||||||||||  gabapentin / Generic mfg., memantine / Generic mfg.
    Journal:  77The α2δ-1-NMDAR1 interaction in the trigeminal ganglion contributes to orofacial ectopic pain following inferior alveolar nerve injury. (Pubmed Central) -  Feb 8, 2022   
    Moreover, inhibition of α2δ-1 by intra-TG administration of gabapentin suppressed the upregulation of the NMDAR1 protein, and the inhibition of NMDAR by intra-TG administration of memantine hydrochloride inhibited the increased expression of α2δ-1 protein induced by IANX. In conclusion, the physical and functional interaction between α2δ-1 and NMDAR1 is critical for the development of orofacial ectopic pain, indicating that α2δ-1, NMDAR1, and the α2δ-1-NMDAR1 complex may represent potential targets for the treatment of orofacial ectopic pain.
  • ||||||||||  memantine / Generic mfg.
    Preclinical, Journal:  Insight into Glutamatergic Involvement in Rewarding Effects of Mephedrone in Rats: In Vivo and Ex Vivo Study. (Pubmed Central) -  Feb 8, 2022   
    In this study, we comprehensively evaluated glutamatergic involvement in rewarding effects of mephedrone using an interdisciplinary approach including (1) behavioural study on effects of memantine (non-selective NMDA antagonist) on expression of mephedrone-induced conditioned place preference (CPP) in rats; (2) evaluation of glutamate concentrations in the hippocampus of rats following 6 days of mephedrone administration, using in vivo magnetic resonance spectroscopy (MRS); and (3) determination of glutamate levels in the hippocampus of rats treated with mephedrone and subjected to MRS, using ion-exchange chromatography...Ex vivo chromatographic analysis did not show significant changes in hippocampal glutamate concentrations; however, it showed similar results as obtained in the MRS study proving its validity. Taken together, the presented study provides new insight into glutamatergic involvement in rewarding properties of mephedrone.
  • ||||||||||  memantine / Generic mfg.
    Preclinical, Journal:  Upregulated NMDAR-mediated GABAergic transmission underlies autistic-like deficits in Htr3a knockout mice. (Pubmed Central) -  Feb 8, 2022   
    Our data indicated that upregulation of the NMDAR in PV interneurons may play a critical role in regulating GABAergic input to pyramidal neurons and maybe involve in the pathogenesis of autism associated with HTR3A deficiency. Therefore, we suggest that the NMDAR system could be considered potential therapeutic target for autism.
  • ||||||||||  memantine / Generic mfg.
    Journal:  CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia. (Pubmed Central) -  Feb 8, 2022   
    Cognitive enhancers (ie, cholinesterase inhibitors and memantine) can provide symptomatic benefit for some individuals with dementia; however, there are circumstances in which the risks of continuing treatment may potentially outweigh benefits...Clinicians should not deprescribe cognitive enhancers in individuals with significant neuropsychiatric symptoms until symptoms have stabilized. CCCDTD5 deprescribing recommendations provide evidence-informed recommendations related to cognitive enhancer deprescribing that will facilitate shared decision making among patients, care partners, and clinicians.
  • ||||||||||  memantine / Generic mfg.
    Journal:  Quantitative systems pharmacology model of the effect of tau hyperphosphorylation on synaptic plasticity. (Pubmed Central) -  Feb 4, 2022   
    Various data on synaptic plasticity in presence of different effectors (amyloid beta, memantine, SSR180711 etc.), available from the literature, are used for verification...It demonstrates that: 1) tau with anti-aggregant properties may lead to a robust LTP, that was even more pronounced than control tau 2) antibody to tau decreases tau hyperhyperphosphorylation and restores LTP reduced by OA influence 3) inhibition of GSK-3b kinase leads attenuates hyperphosphorylation and leads to recovery of LTP The QSP model describes an influence of tau hyperphosphorylation on receptor's excitotoxicity and released calcium from ER (high activity of PP2b, increased intracellular calcium concentration). Our model allows to explore change of LTP under the influence of tau targeting therapy.